BioLinx Polymer

Resolute Polymer

  • Biocompatible BioLinx polymer
  • Extended drug-elution kinetics inhibit neointimal growth
  • Leads to minimal inflammation
  • Provides rapid, complete and functional healing

The revolutionary BioLinx polymer allows for extended delivery of the zotarolimus drug to the tissue. 85% of the drug is eluted by 60 days, and the rest is eluted by 180 days.

Drug-Elution Kinetics

Preclinical porcine data on file at Medtronic, Inc.
1The Resolute stent has a nominal drug dose of 1.6 μg zotarolimus per mm2 of the stent surface area.

 

Inhibition of Neointimal Growth

BMS Control - Resolute DES

Significant inhibition of neointimal growth development compared with Driver bare metal stent controls (p=0.0006).
Pre-clinical results presented on this web page may not be indicative of clinical performance of drug-eluting stents.
28-day results in porcine models. Carter et al., TCT 2006.

DES Polymers

Hypersensitivity to Polymers May be Responsible for Delayed Healing and Late Stent Thrombosis*


Polymer Vessel Impact

*Nebeker et al. JACC Vol 47, No 1, 2006

 

Reduced Inflammation Response with BioLinx Polymer

What Is An Inflammation Score?—Greater Biocompatibility is Associated With Low Inflammation Score


Inflammation Scores

Inflammation scores developed by Dr. Renu Virmani; CVPath Institute Inc.; Schwartz RS et al., Circulation. 2004;110:2498-2505.
1Preclinical data on file at Medtronic, Inc.
2Preclinical data from Abbott Xience V US physicians presentation SE2924433D.
Preclinical results presented in this section may not be indicative of clinical performance of drug-eluting stents.

Resolute DES Allows for Rapid and Complete Endothelial Healing

Full Endothelialisation Achieved by 28 Days in Porcine Models


Resolute DES Endothelial Healing SEM Analysis

128-day small vessel safety study in porcine model (FS144).
2180-day safety study in porcine model (FS129).
3365 days in porcine model (FS142).

 

Resolute DES Allows For Restored Endothelial Function

Higher eNOS Levels


eNos
  • Normal, healthy endothelial cells produce nitric oxide (NO)
  • The eNOS protein, the enzyme that catalyses NO synthesis, is a marker of healthy endothelial cell function
  • Resolute stent shows high eNOS levels, suggesting good NO production and a functional endothelium

4Results as determined by polymerase chain reaction at 28 days. Scores compared with Driver bare metal stent control. Preclinical data in porcine model on file at Medtronic, Inc.

 

Positive Acetylcholine Challenge Response5

5ACh Challenge Response assessed 5 mm proximal to the implanted stent at 28 days.

ACH exposure in a normal, healthy artery causes vasodilation; ACH exposure in a setting of atherosclerosis or endothelial dysfunction causes vasoconstriction


Vessels implanted with Resolute DES Shows Vasodilation Indicating Functional Endothelium


Resolute DES

 

Vessels Implanted With Xience V Shows Vasoconstriction Indicating Dysfunctional Endothelium


Xience V DES

Preclinical porcine data on file at Medtronic, Inc.
Pre-clinical results presented on this web page may not be indicative of clinical performance of drug-eluting stents.

Clinical Data Overview

RESOLUTE All Comers
24 Month Results Summary

 
 

Email Page

Send a link to this page by email along with your comments.
Please enter the information below.

  1. (required)
  2. (required)
  3. (required)